RedHill Biopharma Ltd. (RDHL) - Form 20-F Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended December 31, 2025.
Company Overview: RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company focused on gastrointestinal (GI), infectious diseases, and oncology. The company's primary commercial product is Talicia® (for H. pylori infection), while its pipeline includes five therapeutic candidates (Opaganib, RHB-204, RHB-104, RHB-102, and RHB-107).
Strategic Shift: In October 2025, the company completed a strategic transaction forming Talicia Holdings Inc. (THI), a joint venture with Cumberland Pharmaceuticals Inc. RedHill transferred Talicia® operations to THI, retaining a 70% equity interest. Due to joint control requirements, RedHill lost unilateral control, deconsolidated THI, and now accounts for it as a joint venture. Consequently, Talicia® commercial operations are presented as discontinued operations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (Continuing Ops) | 2025 (Discontinued Ops) | 2024 (Continuing Ops) |
|---|---|---|---|
| Revenues | $0.3 million | $7.5 million | $0.0 million |
| Operating Loss | $(7.9) million | $7.6 million (Income) | $(6.5) million |
| Net Income (Loss) | $(8.1) million | $7.7 million | $0.4 million |
| Total Net Income (Loss) | $(0.4) million | — | $(8.3) million |
| Cash & Equivalents | $4.1 million | — | $4.8 million |
| Net Cash Used in Operating Activities | $(9.7) million | — | $(9.4) million |
| Accumulated Deficit | $(413.8) million | — | $(414.8) million |
Note: 2025 Continuing Operations revenue is derived from a licensing agreement with Hyloris Pharmaceuticals. Discontinued operations include a one-time gain of ~$8.0 million from the loss of control of THI.
Material Changes vs. Prior Period
- Discontinued Operations: The most significant change is the reclassification of Talicia® commercial activities to discontinued operations following the October 2025 joint venture formation with Cumberland. This resulted in a $7.98 million gain on loss of control.
- Revenue Composition: Continuing operations revenue increased from $0 in 2024 to $0.3 million in 2025, driven by the Hyloris license for RHB-102 (Bekinda®).
- Expense Increases: General and Administrative expenses for continuing operations rose to $6.2 million (from $4.9 million in 2024), primarily due to legal expenses related to the Kukbo litigation.
- Financial Income Volatility: Net financial income dropped from $6.8 million in 2024 to a net expense of $0.1 million in 2025. The 2024 figure was inflated by a $8.2 million fair value gain on derivative financial instruments, which did not recur in 2025.
- Asset Structure: Total assets increased to $25.3 million (from $18.0 million in 2024), driven by the $12.0 million investment in the THI joint venture.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. With only $4.1 million in cash and negative operating cash flows of $9.7 million in 2025, the company lacks sufficient resources to fund operations for the next 12 months. Significant additional capital is required.
Liquidity and Capital Resources:
- Financing Agreements: The company has entered into a $25 million Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (Dec 2025) and a $10 million equity line with Alumni Capital LP (June 2025).
- Overdue Obligations: The company has significant past-due obligations related to allowances for deductions from revenue and other liabilities. While some payment rescheduling agreements (up to 24 months) have been finalized, others remain uncertain.
Nasdaq Compliance:
- Minimum Bid Price: Received a deficiency letter on April 8, 2026, for failing to maintain the $1.00 minimum bid price. The company has 180 days (until Oct 5, 2026) to regain compliance.
- Market Value: The company is currently below the proposed $5 million Market Value of Listed Securities (MVLS) rule, posing a delisting risk if the rule is adopted and the company fails to meet the threshold.
Legal Contingencies:
- Kukbo Litigation: RedHill secured a final judgment of over $10.5 million against Kukbo Co. Ltd. (principal + interest + legal fees). While an attachment grant was secured in Korea, collection is not guaranteed. The company has accrued ~$1.4 million in legal fees payable regardless of collection.
Operational Risks:
- Internal Controls: A material weakness in internal control over financial reporting (related to revenue allowance calculations) identified in 2022 remains unremediated as of Dec 31, 2025.
- Geopolitical: Ongoing conflict in Israel and the Middle East poses risks to operations, supply chains, and employee availability.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $4.1 million cash balance against the $9.7 million annual burn rate and the timeline for securing new financing.
- THI Joint Venture Performance: Monitor the commercial performance of Talicia® under the joint venture with Cumberland, as RedHill's future revenue depends on this partnership's success.
- Nasdaq Delisting Risk: Track the ADS bid price to ensure it remains above $1.00 for 10 consecutive days within the 180-day cure period to avoid delisting.
- Kukbo Collection: Assess the likelihood of collecting the $10.5 million judgment against Kukbo, given the company's reliance on this asset for liquidity.
- Internal Control Remediation: Review progress on remediation of the material weakness in internal controls to ensure financial reporting reliability.
- Overdue Liabilities: Confirm the status of negotiations with counterparties regarding past-due obligations to avoid legal proceedings or penalties.